Shuming Huang

Dr. Shuming Huang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Pharmaceutical Biology
Verified
Journal Article
Open access
BTBing Tian
Bing Tian
MTMing Tian
Ming Tian
SHShuming Huang
Shuming Huang
ABSRACT Context: Rhizoma Corydalis (RC) is the dried tubers of Corydalis yanhusuo (Y. H. Chou and Chun C. Hsu) W. T. Wang ex Z. Y. Su and C. Y. Wu (Papaveraceae). Traditionally, RC is used to alleviate pain such as headache, abdominal pain, and epigastric pain. Modern medicine shows that it has analgesic, anti-arrhythmia, and other effects. Objective: We provided an overview of the phytochemical and pharmacological properties of RC as a foundation for its clinical application and further research and development of new drugs. Methods: We collected data of various phytochemical and pharmacological effects of RC from 1982 to 2019. To correlate with existing scientific evidence, we used Google Scholar and the journal databases Scopus, PubMed, and CNKI. ‘Rhizoma Corydalis’, ‘phytochemistry’, and ‘pharmacological effects’ were used as key words. Results: Currently, more than 100 chemical components have been isolated and identified from RC, among which alkaloid is the pimary active component of RC. Based on prior research, RC has antinociceptive, sedative, anti-epileptic, antidepressive and anti-anxiety, acetylcholinesterase inhibitory effect, drug abstinence, anti-arrhythmic, antimyocardial infarction, dilated coronary artery, cerebral ischaemia reperfusion (I/R) injury protection, antihypertensive, antithrombotic, antigastrointestinal ulcer, liver protection, antimicrobial, anti-inflammation, antiviral, and anticancer effects. Conclusions: RC is reported to be effective in treating a variety of diseases. Current pharmacological studies on RC mainly focus on the nervous, circulatory, digestive, and endocrine systems, as well as drug withdrawal. Although experimental data support the beneficial effects of this drug, its physiological activity remains a concern. Nonetheless, this review provides a foundation for future research.

13 June 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
HXHongdan Xu
Hongdan Xu
WLWei Li
Wei Li
BZBo Zhang
Bo Zhang
SHShuming Huang
Shuming Huang
XLXuewei Liu
Xuewei Liu
Estrogen deficiency increases the incidence of female anxiety disorders; however, whether estrogen deficiency alters responses to anxiolytic drugs is unknown. We studied whether long-term estrogen deprivation (ovariectomy, OVX) changes the behavior of mice to anxiolytic drugs (buspirone, diazepam, and venlafaxine), using the elevated plus maze (EPM) test. The percentages of EPM open-arm time and EPM open-arm entries of the OVX mice decreased significantly compared to control, and sham mice 2 months after OVX. The response to buspirone increased in the OVX mice at 1 week, while OVX decreased the response to diazepam at 2 months. Moreover, we found the efficacy of diazepam was significantly decreased, compared to buspirone and venlafaxine, at 2 months. These results suggest that OVX may change responses to different anxiolytic drugs. Not all anti-anxiety drugs appear to be suitable for anxiety caused by estrogen deficiency.